| __timestamp | Alpine Immune Sciences, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 5078000000 |
| Thursday, January 1, 2015 | 6844000 | 4717000000 |
| Friday, January 1, 2016 | 8586000 | 5096000000 |
| Sunday, January 1, 2017 | 6079000 | 4986000000 |
| Monday, January 1, 2018 | 8362000 | 4214000000 |
| Tuesday, January 1, 2019 | 9467000 | 3806000000 |
| Wednesday, January 1, 2020 | 10899000 | 3671000000 |
| Friday, January 1, 2021 | 14560000 | 3528000000 |
| Saturday, January 1, 2022 | 17968000 | 3445000000 |
| Sunday, January 1, 2023 | 22222000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Teva Pharmaceutical Industries Limited and Alpine Immune Sciences, Inc., from 2014 to 2023.
Teva, a giant in the industry, has seen its SG&A expenses decrease by approximately 31% over the decade, from a peak in 2016 to a more streamlined budget in 2023. This reduction reflects strategic cost management amidst challenging market conditions.
Conversely, Alpine Immune Sciences, a smaller yet innovative firm, has experienced a staggering 872% increase in SG&A expenses, highlighting its aggressive growth and expansion strategy. This surge underscores Alpine's commitment to scaling its operations and enhancing its market presence.
These contrasting trends offer a fascinating glimpse into the strategic priorities of established versus emerging pharmaceutical companies.
Eli Lilly and Company and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs TG Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Veracyte, Inc. Trends and Insights
Teva Pharmaceutical Industries Limited and Geron Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Alpine Immune Sciences, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. or CymaBay Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alpine Immune Sciences, Inc. vs Vericel Corporation
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Galapagos NV
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and BioCryst Pharmaceuticals, Inc.